2nd line therapy vildagliptin v oral agents T2D

EDGE demonstrates that in a ‘real-life’ setting, vildagliptin as second oral antihyperglycaemic drugs (OAD) can lower HbA1c to target without well-recognised OAD side effects, more frequently than comparator OADs (International Journal of Clinical Practice)